Skip to main content

Search Videos and More

Showing 1 - 12 of 70 results

Previous| 1 | 2 | 3 ...6 |Next

What specific LDL-C-related endpoints are likely to undergo review and revisions based on the publication of two PCSK9-related trials, ODYSSEY Outcomes and FOURIER?

What specific LDL-C-related endpoints are likely to undergo review and revisions based on the publication of two PCSK9-related trials, ODYSSEY Outcomes and FOURIER?

In the lipid clinic setting, in patients you have treated with PCSK9 inhibitors, what are you finding as far as regimen adherence, toleration, and patient engagement/satisfaction with these injectable strategies?

In the lipid clinic setting, in patients you have treated with PCSK9 inhibitors, what are you finding as far as regimen adherence, toleration, and patient engagement/satisfaction with these injectable strategies?

Given that ODYSSEY Outcomes has shown not only reduction in CV events, but also a reduction in associated, all-cause mortality, what is the role of PCSK9 inhibitors in diabetes patients with a prior ACS event?

Given that ODYSSEY Outcomes has shown not only reduction in CV events, but also a reduction in associated, all-cause mortality, what is the role of PCSK9 inhibitors in diabetes patients with a prior ACS event?

How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor?

How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor?

In which of your patients with FH do you feel PSCK9 inhibitors will become foundational agents, in conjunction with statins, when tolerated?

In which of your patients with FH do you feel PSCK9 inhibitors will become foundational agents, in conjunction with statins, when tolerated?

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

How do you approach younger patients with known, advanced subclinical atherosclerosis?

How do you approach younger patients with known, advanced subclinical atherosclerosis?

Although the AHA Guidelines identify a 70 mg/dL threshold target for patients at high risk for recurrent ACS, do you believe this is merely a “starting point” identifying a minimal level of LDL-C goal attainment?

Although the AHA Guidelines identify a 70 mg/dL threshold target for patients at high risk for recurrent ACS, do you believe this is merely a “starting point” identifying a minimal level of LDL-C goal attainment?

In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors?

In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors?

What should the “threshold” of 70 mg/dL identified in the AHA Guidelines mean to the medical or preventive cardiologist in his/her aspiration to optimize CV risk reduction in high-risk patients with a history of ACS or related high-risk features?

What should the “threshold” of 70 mg/dL identified in the AHA Guidelines mean to the medical or preventive cardiologist in his/her aspiration to optimize CV risk reduction in high-risk patients with a history of ACS or related high-risk features?

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?

Showing 1 - 12 of 70 results

Previous| 1 | 2 | 3 ...6 |Next